Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemoglobinopathy (Disorder) Clear all
Recruiting No phase listed Observational

A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease

NCT04166526
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
FDNIRS-DCS, MRI
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 2 Interventional Results available

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

NCT00115349
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
Interventions
Deferoxamine, Deferiprone (L1)
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 1 Interventional

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

NCT04091737
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Phase 2 Interventional

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

NCT00029731
View directory record Official record
Conditions
Anemia, Sickle Cell, Pneumonia
Interventions
Arginine hydrochloride
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 30, 2026, 2:59 PM EDT
Active, not recruiting Phase 2 Interventional

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

NCT04018937
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 13 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Not applicable Interventional Results available

Hyperbaric Oxygen Therapy in Sickle Cell Pain

NCT03412045
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions
hyperbaric oxygen therapy
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Preventing Sickle Cell Kidney Disease

NCT02373241
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions
Losartan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032
View directory record Official record
Conditions
Thalassemia Major With Severe Transfusional Iron Overload
Interventions
Deferasirox and deferiprone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 4 Interventional Results available

Desmopressin for Bedwetting in Children With SCD

NCT04420585
View directory record Official record
Conditions
Nocturnal Enuresis, Anemia, Sickle Cell
Interventions
Desmopressin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 30, 2026, 2:59 PM EDT
Withdrawn Phase 4 Interventional

Ketamine Infusion for Sickle Cell Pain Crisis

NCT04005209
View directory record Official record
Conditions
Anemia; Sickle-Cell, With Crisis, Acute Pain
Interventions
Ketamine, Pain management
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Sep 30, 2026, 2:59 PM EDT
Completed No phase listed Observational

A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease

NCT02261480
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Blood draw, Nasopharyngeal wash
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Not applicable Interventional

Ultrasound Acute Chest Syndrome Sickle Cell Disease

NCT06880679
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Point of Care Ultrasound
Device
Lead sponsor
Indiana University
Other
Eligibility
Up to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 2:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebral Oxygen Metabolism in Children

NCT04157179
View directory record Official record
Conditions
Sickle Cell Disease, Cerebral Stroke
Interventions
Carbon Dioxide
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 50 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Not applicable Interventional

Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App

NCT04675645
View directory record Official record
Conditions
Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions
HU-Go app
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 25 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 1 Interventional

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol 2.5 MG, Microcrystalline cellulose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

NCT00957931
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Bone marrow transplantation, Mesenchymal Stromal Cells
Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 30, 2026, 2:59 PM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 2 Interventional Results available

Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

NCT00492531
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Oakland, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

NCT01050855
View directory record Official record
Conditions
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Interventions
Reduced-Intensity Conditioning
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 2:59 PM EDT
Not yet recruiting Phase 1 Interventional

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

NCT07799571
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions
Buprenorphine Buccal Film [Belbuca]
Drug
Lead sponsor
Natasha Archer
Other
Eligibility
12 Years to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management

NCT03291613
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Pinpoint App
Other
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
13 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Golden, Colorado • Munster, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 30, 2026, 2:59 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

NCT03825341
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Hydroxyurea, Hydroxyurea Oral Capsule
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Months to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Sep 30, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

NCT02061202
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mometasone Furoate, Placebo
Drug
Lead sponsor
Jeffrey Glassberg
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 30, 2026, 2:59 PM EDT